Whether amino acid mapping (AAM)-based virtual screening of ~12 million commercially available compounds could identify novel non-naphthoquinone scaffolds that inhibit bacterial histidine kinases (HKs) by targeting the conserved H-box region, using waldiomycin's naphthoquinone moiety as the reference descriptor.
Three 4H-pyrido[1,2-a]pyrimidin-4-one derivatives (FF-054, FF-055, FF-060) showed HK inhibitory activity with IC50 values of 4.39–259 µM against WalK, VicK, and EnvZ; FF-055 (IC50 6.92 µM) and FF-060 (IC50 4.39 µM) against VicK outperformed waldiomycin (IC50 25.8 µM), and NMR confirmed direct binding to the EnvZ DHp H-box domain.
No whole-cell antibacterial activity or cytotoxicity data are reported, so clinical relevance is unknown; IC50 values against WalK were weaker than waldiomycin (105–305 µM vs. 13.1 µM) for all new compounds; the AAM hit-selection threshold (0.75) was set empirically with an approximate 10% success rate, and binding affinities were not quantified (e.g., no Kd values).
These compounds are early-stage research tools only—no clinical or antimicrobial application is yet warranted, but the AAM scaffold-hopping method represents a promising structure-independent strategy for finding new leads against bacterial two-component signaling systems, a target class with potential relevance to drug-resistant ESKAPE pathogens.
Explore related topics